CN103097380A - 酪蛋白激酶1δ 及酪蛋白激酶1ε 抑制剂 - Google Patents
酪蛋白激酶1δ 及酪蛋白激酶1ε 抑制剂 Download PDFInfo
- Publication number
- CN103097380A CN103097380A CN2011800394277A CN201180039427A CN103097380A CN 103097380 A CN103097380 A CN 103097380A CN 2011800394277 A CN2011800394277 A CN 2011800394277A CN 201180039427 A CN201180039427 A CN 201180039427A CN 103097380 A CN103097380 A CN 103097380A
- Authority
- CN
- China
- Prior art keywords
- casein kinase
- compound
- disease
- salt
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 B*1=C=**C#C[C@](C(C#O)=NCCC(O)=O)S1 Chemical compound B*1=C=**C#C[C@](C(C#O)=NCCC(O)=O)S1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510100478.6A CN104803997A (zh) | 2010-08-09 | 2011-08-08 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010178549 | 2010-08-09 | ||
JP2010-178549 | 2010-08-09 | ||
PCT/JP2011/068034 WO2012020726A1 (ja) | 2010-08-09 | 2011-08-08 | カゼインキナーゼ1δ及びカゼインキナーゼ1ε阻害剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510100478.6A Division CN104803997A (zh) | 2010-08-09 | 2011-08-08 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103097380A true CN103097380A (zh) | 2013-05-08 |
CN103097380B CN103097380B (zh) | 2015-06-03 |
Family
ID=45567692
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510100478.6A Pending CN104803997A (zh) | 2010-08-09 | 2011-08-08 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
CN201180039427.7A Active CN103097380B (zh) | 2010-08-09 | 2011-08-08 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510100478.6A Pending CN104803997A (zh) | 2010-08-09 | 2011-08-08 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8710231B2 (zh) |
EP (1) | EP2604606B1 (zh) |
JP (1) | JP5181156B2 (zh) |
KR (1) | KR101856266B1 (zh) |
CN (2) | CN104803997A (zh) |
AU (1) | AU2011290238B8 (zh) |
CA (1) | CA2807359C (zh) |
HK (2) | HK1183874A1 (zh) |
IL (1) | IL224612A (zh) |
RU (1) | RU2562833C2 (zh) |
WO (1) | WO2012020726A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104803997A (zh) * | 2010-08-09 | 2015-07-29 | 株式会社创药分子设计 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE060789T2 (hu) * | 2018-07-05 | 2023-04-28 | Bayer Ag | Szubsztituált tiofénkarboxamidok és analógok antibakteriális szerekként |
CA3111848A1 (en) * | 2018-09-09 | 2020-03-12 | Qanatpharma Ag | Use of casein kinase 1 inhibitors for treating vascular diseases |
US20230053307A1 (en) * | 2021-07-19 | 2023-02-16 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating skin disorders and conditions |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003505453A (ja) * | 1999-07-22 | 2003-02-12 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・(エス.セー.エール.アー.エス) | 2−アリールイミノ−2,3−ジヒドロチアゾール類及びそのソマトスタチンレセプターのリガンドとしての使用 |
JP2004530643A (ja) * | 2001-01-12 | 2004-10-07 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・(エス.セー.エール.アー.エス) | 2−アリールイミノ−2,3−ジヒドロチアゾール、その製造方法及びその治療での使用 |
CN1909908A (zh) * | 2004-01-22 | 2007-02-07 | 诺瓦提斯公司 | 用于治疗蛋白激酶依赖性疾病的吡唑并[1,5-a]嘧啶-7-基-胺衍生物 |
JP2008510704A (ja) * | 2004-08-19 | 2008-04-10 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | カゼインキナーゼIεの阻害剤としての3−アリールチオインドール−2−カルボキサミド誘導体及びその類似体 |
JP2008510712A (ja) * | 2004-08-19 | 2008-04-10 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | カゼイン・キナーゼIε阻害剤としての、置換チエノピロールカルボン酸アミド、ピロロチアゾールカルボン酸アミド及び関連する類似化合物 |
WO2009037394A2 (fr) * | 2007-07-19 | 2009-03-26 | Sanofi-Aventis | DERIVES DE 6-CYCLOAMINO-S-(PYRIDAZIN-YL)IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE. |
WO2010092660A1 (ja) * | 2009-02-12 | 2010-08-19 | 株式会社ファルマデザイン | カゼインキナーゼ1δ及びカゼインキナーゼ1ε阻害剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03011196A (es) | 2001-06-08 | 2004-10-28 | Cytovia Inc | 3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos. |
MY140489A (en) * | 2003-12-26 | 2009-12-31 | Eisai R&D Man Co Ltd | 1,2-di (cyclic) substituted benzene compounds |
US7531539B2 (en) * | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
JP2009245477A (ja) | 2008-03-28 | 2009-10-22 | Hoya Corp | 垂直磁気記録媒体 |
JP5181156B2 (ja) * | 2010-08-09 | 2013-04-10 | 株式会社ファルマデザイン | カゼインキナーゼ1δ及びカゼインキナーゼ1ε阻害剤 |
-
2011
- 2011-08-08 JP JP2012528666A patent/JP5181156B2/ja active Active
- 2011-08-08 US US13/816,180 patent/US8710231B2/en active Active
- 2011-08-08 EP EP11816390.6A patent/EP2604606B1/en active Active
- 2011-08-08 WO PCT/JP2011/068034 patent/WO2012020726A1/ja active Application Filing
- 2011-08-08 CA CA2807359A patent/CA2807359C/en active Active
- 2011-08-08 CN CN201510100478.6A patent/CN104803997A/zh active Pending
- 2011-08-08 CN CN201180039427.7A patent/CN103097380B/zh active Active
- 2011-08-08 KR KR1020137005642A patent/KR101856266B1/ko active IP Right Grant
- 2011-08-08 RU RU2013107659/04A patent/RU2562833C2/ru active
- 2011-08-08 AU AU2011290238A patent/AU2011290238B8/en active Active
-
2013
- 2013-02-07 IL IL224612A patent/IL224612A/en active IP Right Grant
- 2013-10-10 HK HK13111396.2A patent/HK1183874A1/zh unknown
-
2015
- 2015-12-25 HK HK15112726.9A patent/HK1211926A1/zh unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003505453A (ja) * | 1999-07-22 | 2003-02-12 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・(エス.セー.エール.アー.エス) | 2−アリールイミノ−2,3−ジヒドロチアゾール類及びそのソマトスタチンレセプターのリガンドとしての使用 |
JP2004530643A (ja) * | 2001-01-12 | 2004-10-07 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・(エス.セー.エール.アー.エス) | 2−アリールイミノ−2,3−ジヒドロチアゾール、その製造方法及びその治療での使用 |
CN1909908A (zh) * | 2004-01-22 | 2007-02-07 | 诺瓦提斯公司 | 用于治疗蛋白激酶依赖性疾病的吡唑并[1,5-a]嘧啶-7-基-胺衍生物 |
JP2008510704A (ja) * | 2004-08-19 | 2008-04-10 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | カゼインキナーゼIεの阻害剤としての3−アリールチオインドール−2−カルボキサミド誘導体及びその類似体 |
JP2008510712A (ja) * | 2004-08-19 | 2008-04-10 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | カゼイン・キナーゼIε阻害剤としての、置換チエノピロールカルボン酸アミド、ピロロチアゾールカルボン酸アミド及び関連する類似化合物 |
WO2009037394A2 (fr) * | 2007-07-19 | 2009-03-26 | Sanofi-Aventis | DERIVES DE 6-CYCLOAMINO-S-(PYRIDAZIN-YL)IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE. |
WO2010092660A1 (ja) * | 2009-02-12 | 2010-08-19 | 株式会社ファルマデザイン | カゼインキナーゼ1δ及びカゼインキナーゼ1ε阻害剤 |
Non-Patent Citations (4)
Title |
---|
CHRISTIAN PEIFER: "3,4-Diaryl-isoxazoles and -imidazoles as Potent Dual Inhibitors of p38r Mitogen Activated Protein Kinase and Casein Kinase 1δ", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
MASAKO OKAMOTO: "Structure–activity relationship of novel DAPK inhibitors identified by structure-based virtual screening", 《BIOORGANIC MEDICINAL CHEMISTRY》 * |
MASAKO OKAMOTO: "Structure–activity relationship of novel DAPK inhibitors identified by structure-based virtual screening", 《BIOORGANIC MEDICINAL CHEMISTRY》, vol. 18, 15 February 2010 (2010-02-15), pages 2728 - 2734, XP027027281 * |
刘炜等: "I型酪蛋白激酶的研究进展", 《西北植物学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104803997A (zh) * | 2010-08-09 | 2015-07-29 | 株式会社创药分子设计 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
Also Published As
Publication number | Publication date |
---|---|
JP5181156B2 (ja) | 2013-04-10 |
RU2013107659A (ru) | 2014-09-20 |
IL224612A (en) | 2016-05-31 |
US20130137730A1 (en) | 2013-05-30 |
CN103097380B (zh) | 2015-06-03 |
EP2604606A4 (en) | 2013-08-07 |
CN104803997A (zh) | 2015-07-29 |
JPWO2012020726A1 (ja) | 2013-10-28 |
AU2011290238A1 (en) | 2013-03-21 |
HK1211926A1 (zh) | 2016-06-03 |
CA2807359A1 (en) | 2012-02-16 |
EP2604606A1 (en) | 2013-06-19 |
KR20140000666A (ko) | 2014-01-03 |
AU2011290238B8 (en) | 2015-09-03 |
EP2604606B1 (en) | 2014-10-08 |
KR101856266B1 (ko) | 2018-05-09 |
US8710231B2 (en) | 2014-04-29 |
CA2807359C (en) | 2020-07-07 |
WO2012020726A1 (ja) | 2012-02-16 |
AU2011290238B2 (en) | 2014-07-17 |
HK1183874A1 (zh) | 2014-01-10 |
RU2562833C2 (ru) | 2015-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5913292B2 (ja) | 代謝を調節する組成物および方法 | |
US7812025B2 (en) | Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder | |
JP2024037891A (ja) | 黒色腫の治療のための組合せ医薬 | |
CN104395319A (zh) | 用作ampk的活化剂的噻吩并吡啶酮衍生物 | |
BR112020026062A2 (pt) | derivados de benzodiazepina, composições, e métodos para o tratamento de comprometimento cognitivo | |
CN103957916A (zh) | 用于治疗代谢疾病和相关失调的单酰甘油脂肪酶抑制剂 | |
CN103380112A (zh) | 作为s1p受体调节剂的吲哚衍生物 | |
CN103097380B (zh) | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 | |
JP4748823B2 (ja) | カゼインキナーゼ1δ及びカゼインキナーゼ1ε阻害剤 | |
JP7167235B2 (ja) | 自閉症スペクトラム障害の予防または治療剤 | |
JP7054289B2 (ja) | 医薬有効成分のスクリーニング方法、製造方法及び設計方法 | |
WO2015163431A1 (ja) | 片頭痛治療剤 | |
CN112300145A (zh) | 一类靶向stat3双功能磷酸化位点的三芳香环类化合物及其应用 | |
CN114761382A (zh) | Magl抑制剂的晶型 | |
JP2014201578A (ja) | 線維筋痛症治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1183874 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NB HEALTH LAB CO., LTD. Free format text: FORMER OWNER: PHARMA DESIGN INC Effective date: 20150827 Free format text: FORMER OWNER: NB HEALTH LAB CO., LTD. Effective date: 20150827 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150827 Address after: Hokkaido Japan Patentee after: NB Health Laboratory Co. Ltd. Address before: Tokyo, Japan, Japan Patentee before: Pharmadesign, Inc. Patentee before: NB Health Laboratory Co. Ltd. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1183874 Country of ref document: HK |